

# Anti-IL-17 $\alpha$ (Netakimab), Human IgG1 Antibody

08/20

---

**CATALOG NO.:** A2206-100 (100  $\mu$ g)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a humanized IgG1 monoclonal antibody that targets IL-17 $\alpha$  and prevents the interaction with its receptor (IL-17R), thus blocking IL-17 $\alpha$  mediated inflammatory and immune responses. IL-17 $\alpha$  is a pro-inflammatory cytokine that plays an important role in inflammatory diseases such as psoriatic arthritis and ankylosing spondylitis (AS). In the heavy chain of the original antibody, V<sub>H</sub> variable domain is replaced with the V<sub>H</sub>H domain of *Lama glama* that possesses a long complementary determining region (CDR-H3) that allows the antibody to bind IL-17 with a higher affinity. The original antibody-drug has been approved to treat moderate-to-severe plaque psoriasis. Additionally, the drug is undergoing clinical trials to treat ankylosing spondylitis (AS).

**ALTERNATE NAMES:** BCD-085, BCD085, BCD 085, IL17a, IL17, CTLA8, IL-17, CTLA-8, IL-17A

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human IL-17 $\alpha$

**CAS NUMBER:** 1796570-08-5

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-12 $\beta$  (Ustekinumab), Human IgG1 Antibody (A2137)  
 Anti-IL-17 $\alpha$  (Ixekizumab), Humanized Antibody (A2149)  
 Anti-IL23 $\alpha$  (Mirikizumab), Humanized Antibody (A2174)  
 Anti-IL-4R $\alpha$  (Dupilumab), Human IgG4 Antibody (A2148)  
 Anti-IL-17R $\alpha$  (Brodalumab), Human IgG2 Antibody (A2155)

**FOR RESEARCH USE ONLY! Not to be used on humans.**